Luye Pharma Group Ltd. (2186.HK)
HKD 2.17
(-2.25%)
HKD 2.17
(-2.25%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 25.49 Billion CNY | 5.12% |
| 2022 | 24.24 Billion CNY | 7.38% |
| 2021 | 22.58 Billion CNY | 9.46% |
| 2020 | 20.63 Billion CNY | 6.82% |
| 2019 | 19.31 Billion CNY | 10.12% |
| 2018 | 17.53 Billion CNY | 62.99% |
| 2017 | 10.76 Billion CNY | 16.89% |
| 2016 | 9.2 Billion CNY | 30.53% |
| 2015 | 7.05 Billion CNY | 15.04% |
| 2014 | 6.13 Billion CNY | 80.98% |
| 2013 | 3.38 Billion CNY | 26.51% |
| 2012 | 2.67 Billion CNY | 9.1% |
| 2011 | 2.45 Billion CNY | 34.7% |
| 2010 | 1.82 Billion CNY | 19.57% |
| 2009 | 1.52 Billion CNY | 42.87% |
| 2008 | 1.06 Billion CNY | -5.88% |
| 2007 | 1.13 Billion CNY | 35.05% |
| 2006 | 839.18 Million CNY | 113.54% |
| 2005 | 392.99 Million CNY | 5.35% |
| 2004 | 373.04 Million CNY | 36.38% |
| 2003 | 273.54 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 27.19 Billion CNY | 6.7% |
| 2024 Q2 | 27.19 Billion CNY | 0.0% |
| 2023 Q3 | 25.49 Billion CNY | -3.08% |
| 2023 Q2 | 26.3 Billion CNY | 0.0% |
| 2023 Q1 | 26.3 Billion CNY | 8.46% |
| 2023 FY | 25.49 Billion CNY | 5.12% |
| 2023 Q4 | 25.49 Billion CNY | 0.0% |
| 2022 Q3 | 24.24 Billion CNY | 7.45% |
| 2022 Q2 | 22.56 Billion CNY | 0.0% |
| 2022 Q1 | 22.56 Billion CNY | -0.06% |
| 2022 FY | 24.24 Billion CNY | 7.38% |
| 2022 Q4 | 24.24 Billion CNY | 0.0% |
| 2021 Q3 | 22.58 Billion CNY | 3.38% |
| 2021 Q4 | 22.58 Billion CNY | 0.0% |
| 2021 Q1 | 21.84 Billion CNY | 5.88% |
| 2021 Q2 | 21.84 Billion CNY | 0.0% |
| 2021 FY | 22.58 Billion CNY | 9.46% |
| 2020 Q4 | 20.63 Billion CNY | 0.0% |
| 2020 Q1 | 19.56 Billion CNY | 1.3% |
| 2020 FY | 20.63 Billion CNY | 6.82% |
| 2020 Q3 | 20.63 Billion CNY | 5.45% |
| 2020 Q2 | 19.56 Billion CNY | 0.0% |
| 2019 Q3 | 19.4 Billion CNY | 4.37% |
| 2019 FY | 19.31 Billion CNY | 10.12% |
| 2019 Q1 | 18.59 Billion CNY | 6.03% |
| 2019 Q2 | 18.59 Billion CNY | 0.0% |
| 2019 Q4 | 19.31 Billion CNY | -0.48% |
| 2018 Q2 | 16.15 Billion CNY | 0.0% |
| 2018 Q1 | 16.15 Billion CNY | 50.15% |
| 2018 Q3 | 17.53 Billion CNY | 8.55% |
| 2018 Q4 | 17.53 Billion CNY | 0.0% |
| 2018 FY | 17.53 Billion CNY | 62.99% |
| 2017 Q2 | 10.82 Billion CNY | 0.0% |
| 2017 FY | 10.76 Billion CNY | 16.89% |
| 2017 Q4 | 10.76 Billion CNY | 0.0% |
| 2017 Q3 | 10.76 Billion CNY | -0.62% |
| 2017 Q1 | 10.82 Billion CNY | 17.62% |
| 2016 Q2 | 9.26 Billion CNY | 0.0% |
| 2016 Q3 | 9.2 Billion CNY | -0.62% |
| 2016 Q4 | 9.2 Billion CNY | 0.0% |
| 2016 FY | 9.2 Billion CNY | 30.53% |
| 2016 Q1 | 9.26 Billion CNY | 31.34% |
| 2015 Q4 | 7.05 Billion CNY | 0.0% |
| 2015 Q3 | 7.05 Billion CNY | 1.57% |
| 2015 Q2 | 6.94 Billion CNY | 0.0% |
| 2015 Q1 | 6.94 Billion CNY | 13.26% |
| 2015 FY | 7.05 Billion CNY | 15.04% |
| 2014 FY | 6.13 Billion CNY | 80.98% |
| 2014 Q2 | 3.46 Billion CNY | 0.0% |
| 2014 Q1 | 3.46 Billion CNY | 2.27% |
| 2014 Q3 | 6.13 Billion CNY | 76.96% |
| 2014 Q4 | 6.13 Billion CNY | 0.0% |
| 2013 Q1 | - CNY | 0.0% |
| 2013 FY | 3.38 Billion CNY | 26.51% |
| 2013 Q4 | 3.38 Billion CNY | 0.0% |
| 2013 Q3 | 3.38 Billion CNY | 0.0% |
| 2012 Q1 | 2.58 Billion CNY | 5.29% |
| 2012 Q2 | 2.66 Billion CNY | 3.31% |
| 2012 FY | 2.67 Billion CNY | 9.1% |
| 2011 Q2 | 2.04 Billion CNY | 8.29% |
| 2011 FY | 2.45 Billion CNY | 34.7% |
| 2011 Q3 | 2.33 Billion CNY | 14.48% |
| 2011 Q4 | 2.45 Billion CNY | 4.89% |
| 2011 Q1 | 1.88 Billion CNY | 3.59% |
| 2010 Q1 | 1.62 Billion CNY | 6.87% |
| 2010 FY | 1.82 Billion CNY | 19.57% |
| 2010 Q4 | 1.82 Billion CNY | 2.45% |
| 2010 Q3 | 1.77 Billion CNY | 4.46% |
| 2010 Q2 | 1.7 Billion CNY | 4.54% |
| 2009 FY | 1.52 Billion CNY | 42.87% |
| 2009 Q4 | 1.52 Billion CNY | 0.0% |
| 2008 FY | 1.06 Billion CNY | -5.88% |
| 2007 FY | 1.13 Billion CNY | 35.05% |
| 2006 FY | 839.18 Million CNY | 113.54% |
| 2005 FY | 392.99 Million CNY | 5.35% |
| 2004 FY | 373.04 Million CNY | 36.38% |
| 2003 FY | 273.54 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| CSPC Pharmaceutical Group Limited | 50.95 Billion HKD | 49.976% |